Neuland Laboratories Limited — PPTs, 10-02-2025: Investor Presentation

Q3FY25 reported total income of Rs. 401.9 crore, reflecting a marginal 1.8% year-on-year increase. The company generated EBITDA of Rs. 90.3 crore, which decreased by 26.4%, resulting in an EBITDA margin of 22.5%, down 860 bps YoY. Profit after tax was Rs. 101.4 crore, up 25.6% YoY, benefitting from an exceptional item of Rs. 55.8 crore related to investment property. Net debt stands at Rs. (185.1) crore, improving from Rs. (44.6) crore YoY.

Management highlighted steady revenue contributions from key molecules, especially within CMS and GDS segments. There is increasing customer interest particularly in peptide manufacturing, prompting further capital investment to scale capacity. Notable cash flow generation of Rs. 70.8 crore and a capex increase to Rs. 147 crore underscores growth initiatives. The company maintains a positive outlook, with plans to enhance operational efficiency and capacity in response to customer demand.

With a shift towards higher-margin segments, Neuland Labs is positioning itself for sustainable growth amidst evolving market dynamics.